Sulfonylurea
Glimepiride
GLIMEPIRIDE
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.49 to -0.63) | 0.68 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.08 (-1.56 to -0.60) | 0.70 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.16 (-1.68 to 0.01) | 0.45 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.01 (-1.85 to 0.20) | 0.58 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.48 (1.03 to 3.91) | 0.12 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.29 (0.41 to 4.15) | 0.21 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.83 (1.48 to 8.45) | 0.48 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.78 (1.63 to 7.88) | 0.51 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.53 (0.07 to 2.79) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.42 (0.05 to 2.29) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 14.26 (4.96 to 41.44) | 0.06 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 10.47 (4.25 to 26.79) | 0.07 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.73 (1.89 to 6.86) | 0.17 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.34 (1.54 to 6.91) | 0.19 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.20 (0.78 to 12.35) | 0.20 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.03 (0.59 to 13.24) | 0.23 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.75 (-3.21 to 1.71) | 0.31 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.71 (-3.86 to 2.71) | 0.37 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.10 (0.88 to 1.35) | 0.41 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.02 (0.79 to 1.29) | 0.45 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.55 (0.12 to 1.90) | 0.78 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.58 (0.12 to 2.15) | 0.75 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.32 (0.19 to 0.53) | 0.90 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.37 (0.19 to 0.70) | 0.79 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.46 (0.24 to 0.83) | 0.87 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.50 (0.22 to 1.06) | 0.81 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.56 (0.38 to 0.81) | 0.87 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.63 (0.41 to 0.95) | 0.82 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.06 (0.00 to 0.57) | 0.96 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.06 (0.00 to 0.61) | 0.94 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.68 (0.07 to 6.52) | 0.52 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.40 (0.04 to 3.59) | 0.56 |
Trials
- GRADEGlycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study2013 · 5,047 randomized · 365.26 weeks
- AWARD-CHN1The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus2012 · 737 randomized · 26 weeks
- NCT01425580Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin2012 · 62 randomized · 18 weeks
- NCT00775684A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes2008 · 47 randomized · 26.07 weeks
- NCT00359762Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)2006 · 1,029 randomized · 234.81 weeks
- LEAD-2Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes2006 · 1,091 randomized · 26 weeks